About ARYA Sciences Acquisition Corp IV
ARYA Sciences Acquisition Corp IV focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York. Address: 51 Astor Place, 10th Floor, New York, NY, United States, 10003
ARYA Sciences Acquisition Corp IV News and around…
Latest news about ARYA Sciences Acquisition Corp IV (ARYD) common stock and company :
BALA CYNWYD, PA / ACCESSWIRE / October 6, 2021 / Brodsky & Smith reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will,
NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: Inotiv, Inc. (NASDAQ: NOTV) Inotiv has agreed to merge with Envigo RMS Holding Corp. Under the p
In SPAC news this week, Amicus Therapeutics announced its intent to sell its gene therapy unit to ARYA Sciences Acquisition Corp IV, a SPAC sponsored by Perceptive Advisors.
WILMINGTON, Del., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating ARYA Sciences Acquisition Corp. IV (“ARYA”) (NASDAQ CM: ARYD) regarding possible breaches of fiduciary duties and other violations of law related to ARYA’s agreement to merger with Amicus Therapeutics. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-arya-sciences-acquisition-corp-iv. You may also contact Seth D. Rigrodsky or Gina M. Serra cost a
Shares of Amicus Therapeutics Inc. were up 5.6% in premarket trading on Thursday, the day after the company announced a deal to sell its gene therapy business to ARYA Sciences Acquisition Corp IV , a special purpose acquisition company sponsored by Perceptive Advisors. Amicus will have a 36% stake in the new company, which will be called Caritas Therapeutics Inc. It will retain commercialization rights to the Fabry and Pompe gene therapy programs. Amicus chair and CEO John Crowley will become ch
("Amicus") (NASDAQ:FOLD), and result in Amicus' gene therapy business becoming Caritas Therapeutics, Inc., ("Caritas"), which will be a publicly-listed company.
Amicus Therapeutics Inc(NASDAQ: FOLD) hasagreed to spin off its gene therapy businesstoSciences Acquisition ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...